Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
SanBio Co ( (JP:4592) ) has provided an update.
SanBio Co., Ltd. has secured a committed credit line agreement with MUFG Bank, Ltd. to support the commercialization of its product, AKUUGO, which has received conditional approval. The financial arrangement is expected to have a minor impact on the company’s earnings for the fiscal year ending January 2026.
The most recent analyst rating on (JP:4592) stock is a Sell with a Yen840.00 price target. To see the full list of analyst forecasts on SanBio Co stock, see the JP:4592 Stock Forecast page.
More about SanBio Co
SanBio Co., Ltd. operates in the biotechnology industry, focusing on developing regenerative cell therapies for neurological disorders. Their primary product, AKUUGO, is aimed at intracranial implantation, and the company is working towards its commercialization.
Average Trading Volume: 5,064,093
Technical Sentiment Signal: Buy
Current Market Cap: Yen149.9B
For a thorough assessment of 4592 stock, go to TipRanks’ Stock Analysis page.